Publications

 


  • 471. Prostate-specific antigen testing in Tyrol, Austria: prostate cancer mortality reduction was supported by an update with mortality data up to 2008.

    Schröder FH, Zappa M, 2012

    Journal: Int J Public Health
    Reference: Feb;57(1):45-7.

    paper

  • 470. Screening – balancing between advantages and disadvantages.

    Hugosson J, Carlsson S, 2012

    Journal: Lakartidningen
    Reference: Feb 22-28;109(8):398-402.

  • 469. Reply from authors re: Peter C. Albertsen. How best to use our tools? Eur Urol 2012;62:201-2.

    Bul M, Roobol MJ, 2012

    Journal: Eur Urol
    Reference: Aug;62(2):203.

    paper

  • 468. Radical prostatectomy for low-risk prostate cancer following initial active surveillance: results from a prospective observational cohort.

    Bul M, Zhu X, Rannikko A, Staerman F, Valdagni R, Pickles T, Bangma CH, Roobol MJ, 2012

    Journal: Eur Urol
    Reference: Aug;62(2):195-200.

    paper

  • 467. Comment on the US Preventive Services Task Force’s draft recommendation on screening for prostate cancer.

    Kwiatkowski M, Klotz L, Hugosson J, Recker F, 2012

    Journal: Eur Urol
    Reference: Apr;61(4):851-4.

    paper

  • 466. Risk-based prostate cancer screening.

    Zhu X, Albertsen PC, Andriole GL, Roobol MJ, Schröder FH, Vickers AJ, 2012

    Journal: Eur Urol
    Reference: Apr;61(4):652-61.

    paper

  • 465. Importance of prostate volume in the European Randomized study of Screening for Prostate Cancer (ERSPC) risk calculators: results from the prostate biopsy collaborative group.

    Roobol MJ, Schröder FH, Hugosson J, Jones JS, Kattan MW, Klein EA, Hamdy F, Neal D, Donovan J, Parekh DJ, Ankerst D, Bartsch G, Klocker H, Horninger W, Benchikh A, Salama G, Villers A, Freedland SJ, Moreira DM, Vickers AJ, Lilja H, Steyerberg EW., 2012

    Journal: World J Urol
    Reference: Apr;30(2):149-55.

    paper

  • 464. The absence of voiding symptoms in men with a prostate-specific antigen (PSA) concentration of >= 3,0 ng/ml is an independent risk factor for prostate cancer: results from the Gothenburg Randomized Screening Trial.

    Franlund M, Carlsson S, Stranne J, Aus G, Hugosson J, 2012

    Journal: BJU Int
    Reference: Sep;110(5):638-43.

    paper

  • 463. Screening for prostate cancer.

    Carlsson S, Vickers A, Lilja H, Hugosson J, 2012

    Journal: Ann Intern Med
    Reference: Apr 3;156(7):539; author reply 540.

    paper

  • 462. Screening for prostate cancer: early detection or overdetection?

    Vickers AJ, Roobol MJ, Lilja H, 2012

    Journal: Annu Rev Med
    Reference: 63:161-70.

    paper

  • 461. Active surveillance and radical prostatectomy.

    Bangma CH, 2011

    Journal: Eur J Cancer
    Reference: Sep;47 Suppl 3:S355-6.

    paper

  • 460. Screening for prostate cancer.

    Schröder FH, 2011

    Journal: Eur J Cancer
    Reference: Sep;47 Suppl 3:S164-70.

    paper

  • 459. High accuracy of Swedish death certificates in men participating in screening for prostate cancer: a comparative study of official death certificates with a cause of death committee using a standardized algorithm.

    Godtman R, Holmberg E, Stranne J, Hugosson J, 2011

    Journal: Scan J Urol Nephrol
    Reference: Sep;45(4):226-32.

    paper

  • 458. Comparison of risk calculators from the Prostate Cancer Prevention Trial and the European Randomized study of Screening for Prostate Cancer in a contemporary Canadian cohort.

    Trottier G, Roobol MJ, Lawrentschuk N, Boström PJ, Fernandes KA, Finelli A, Chadwick K, Evans A, van der Kwast TH, Toi A, Zlotta AR, Fleshner NE, 2011

    Journal: BJU Int
    Reference: Oct;108(8 Pt 2):E237-44.

    paper

  • 457. Defining and predicting indolent and low risk prostate cancer.

    Bangma CH, Roobol MJ, 2011

    Journal: Crit Rev Oncol Hematol
    Reference: Oct 25.

    paper

  • 456. Stratifying risk – the US Preventive Services Task Force and prostate-cancer screening.

    Schröder FH, 2011

    Journal: N Engl J Med
    Reference: Nov 24;365(21):1953-5.

    paper

  • 455. Number of screens for overdetection as an indicator of absolute risk of overdiagnosis in prostate cancer screening.

    Wu GH, Auvinen A, Määttänen L, Tammela TL, Stenman UH, Hakama M, Yen AM, Chen HH, 2011

    Journal: Int J Cancer
    Reference: 14-11-02

    paper

  • 454. Screening for prostate cancer – the controversy continues, but can it be resolved?

    Bul M, Schröder FH, 2011

    Journal: Acta Oncol
    Reference: Jun;50 Suppl 1:4-11.

    paper

  • 453. Study has major shortcomings.

    Schröder FH, 2011

    Journal: BMJ
    Reference: 14-06-14

    paper

  • 452. How does early detection by screening affect disease progression? Modeling estimated benefits in prostate cancer screening.

    Wever EM, Draisma G, Heijnsdijk EA, de Koning HJ, 2011

    Journal: Med Decis Making
    Reference: Jul-Aug;31(4):550-8.

    paper

  • 451. Re: Prospective evaluation of operating characteristics of prostate cancer detection biomarkers.

    Roobol MJ, 2011

    Journal: Eur Urol
    Reference: Jul;60(1):177-8.

    paper

  • 450. A critical analysis of the tumor volume threshold for clinically insignificant prostate cancer using a data set of a randomized screening trial.

    Wolters T, Roobol MJ, van Leeuwen PJ, van den Bergh RC, Hoedemaeker RF, van Leenders GJ, Schröder FH, van der Kwast TH, 2011

    Journal: J Urol
    Reference: Jan;185(1):121-5.

    paper

  • 449. Prostate cancer detection and dutasteride: utility and limitations of prostate-specific antigen in men with previous negative biopsies.

    van Leeuwen PJ, Kölble K, Huland H, Hambrock T, Barentsz J, Schröder FH, 2011

    Journal: Eur Urol
    Reference: Feb;59(2):183-90.

    paper

  • 448. Number needed to screen – how can we project outside context?

    Auvinen A, 2011

    Journal: J Clin Epidemiol
    Reference: Dec;64(12):1275-6.

    paper

  • 447. False-positive screening results in the European randomized study of screening for prostate cancer.

    Kilpeläinen TP, Tammela TL, Roobol M, Hugosson J, Ciatto S, Nelen V, Moss S, Määttänen L, Auvinen A, 2011

    Journal: Eur J Cancer
    Reference: Dec;47(18):2698-705.

    paper

  • 446. Critical assessment of prebiopsy parameters for predicting prostate cancer metastasis and mortality.

    van Leeuwen PJ, van den Bergh RC, Wolters T, Zhu X, Bul M, Schröder FH, Bangma CH, Roobol MJ, 2011

    Journal: Can J Urol
    Reference: Dec;18(6):6018-24.

  • 445. Identifying and characterizing ‘escapes’-men who develop metastases or die from prostate cancer despite screening (ERSPC, section Rotterdam).

    Zhu X, van Leeuwen PJ, Bul M, Bangma CH, Roobol MJ, Schröder FH, 2011

    Journal: Int J Cancer
    Reference: Dec 15;129(12):2847-54.

    paper

  • 444. Disease-specific survival of men with prostate cancer detected during the screening interval: results of the European randomized study of screening for prostate cancer-Rotterdam after 11 years of follow-up.

    Zhu X, van Leeuwen PJ, Bul M, Otto SJ, de Koning HJ, Bangma CH, Schröder FH, Roobol MJ, 2011

    Journal: Eur Urol
    Reference: Aug;60(2):330-6.

    paper

  • 443. Updating the prostate cancer risk indicator for contemporary biopsy schemes.

    Bul M, Delongchamps NB, Steyerberg EW, de la Roza G, van Leeuwen PJ, Zhu X, van Vugt HA, Haas GP, Schröder FH, Roobol MJ, 2011

    Journal: Can J Urol
    Reference: Apr;18(2):5625-9.

    paper

  • 442. Prostate cancer around the world. An Overview.

    Schröder FH, 2010

    Journal: Urol Oncol
    Reference: Nov-Dec;28(6):663-7.

  • 441. The excess burden of side-effects from treatment in men allocated to screening for prostate cancer. The Göteborg randomised population-based prostate cancer screening trial.

    Carlsson S, Aus G, Bergdahl S, Khatami A, Lodding P, Stranne J, Hugosson J, 2011

    Journal: Eur J Cancer
    Reference: Mar;47(4):545-53

    paper

  • 440. Prostate cancer diagnosed after prostate-specific antigen testing of men without clinical signs of the disease: a population-based study from the National Prostate Cancer Register of Sweden.

    Bratt O, Berglund A, Adolfsson J, Johansson JE, Törnblom M, Stattin P; Steering Committee of the Swedish National Prostate Cancer Register., 2010

    Journal: Scand J Urol Nephrol.
    Reference: Dec;44(6):384-90

    paper

  • 439. Mortality results from the Göteborg randomised population-based prostate-cancer screening trial.

    Hugosson J, Carlsson S, Aus G, Bergdahl S, Khatami A, Lodding P, Pihl CG, Stranne J, Holmberg E, Lilja H., 2010

    Journal: Lancet Oncology
    Reference: Aug;11(8):725-32

    paper

  • 438. A Risk-Stratified Approach to Prostate-Specific Antigen Screening.

    Keto CJ, Freedland SJ, 2011

    Journal: Eur Urol
    Reference: 59:506-508

    paper

  • 437. Prostate Cancer Incidence and Disease-Specific Survival of Men with Initial Prostate-Specific Antigen Less Than 3.0ng/ml Who Are Participating in ERSPC Rotterdam.

    Bul M, van Leeuwen PJ, Zhu X, Schröder FH, Roobol MJ., 2011

    Journal: Eur Urol
    Reference: 59;498-505

    paper

  • 436. PSA-based prostate cancer screening: the role of active surveillance and informed and shared decision making.

    Venderbos LD, Roobol MJ., 2011

    Journal: Asian J Androl
    Reference: Mar;13(2):219-24.

    paper

  • 435. Disease-specific mortality may underestimate the total effect of prostate cancer screening.

    van Leeuwen PJ, Kranse R, Hakulinen T, Roobol MJ, de Koning HJ, Bangma CH, Schröder FH., 2010

    Journal: J Med screening
    Reference: 17(4):204-10.

    paper

  • 434. Meta-analysis finds screening for prostate cancer with PSA does not reduce prostate cancer-related or all-cause mortality but results likely due to heterogeneity – the two highest quality studies identified do find prostate cancer-related mortality reductions.

    Roobol MJ, Carlsson S, Hugosson J, 2011

    Journal: Evid Based Med
    Reference: Feb;16(1):20-1

  • 433. Prediction of prostate cancer in unscreened men: External validation of a risk calculator.

    van Vugt HA, Roobol MJ, Kranse R, Määttänen L, Finne P, Hugosson J, Bangma CH, Schröder FH, Steyerberg EW, 2011

    Journal: Eur J Cancer
    Reference: Apr;47(6):903-9.

    paper

  • 432. Epilogue: Different approaches for prostate cancer screening in the EU?

    Schröder FH, Denis L, Roobol MJ, 2010

    Journal: Eur J Cancer
    Reference: 46(2010):3120-3125.

  • 431. On the use of prostate-specific antigen for screening of prostate cancer in European Randomised Study for Screening of Prostate Cancer

    Bangma CH,van Schaik RH, Blijenberg BG, Roobol MJ, Lilja H, Stenman U-H, 2010

    Journal: Eur J Cancer
    Reference: 46 (2010):3109-3119.

    paper

  • 430. Lead-time in the European Randomised Study of Screening for Prostate Cancer

    Finne P, Fallah M, Hakama M, Ciatto S, Hugosson J, de Koning HJ, Moss SM, Nelen V, Auvinen A, 2010

    Journal: Eur J Cancer
    Reference: 46(2010):3102-3108.

    paper

  • 429. Latest results from the UK trials evaluating prostate cancer screening and treatment: The CAP and ProtecT studies

    Lane JA, Hamdy FC, Martin RM, Turner EL, Neal DE, Donovan JL, 2010

    Journal: Eur J Cancer
    Reference: 46(2010):3095-3101.

    paper

  • 428. Interval cancers in the Antwerp European randomised study of screening for prostate cancer study, using a 6 year screening interval

    Nelen V, Thys G, Hermans A, D’Hooge K, Dourcy-Belle-Rose B, Coebergh J-W, Roobol M, Denis L, 2010

    Journal: Eur J Cancer
    Reference: 46(2010):3090-3094.

    paper

  • 427. Change of tumour characteristics and treatment over time in both arms of the European Randomized study of Screening for Prostate Cancer

    Boevee SJ, Venderbos LDF, Tammela TLJ, Nelen V, Ciatto S, Kwiatkowski M, Paez A, Malavaud B, Hugosson J, Roobol MJ, 2010

    Journal: Eur J Cancer
    Reference: 46(2010):3082-3089.

    paper

  • 426. Deciding on PSA-screening – Quality of current consumer information on the Internet

    Korfage IJ, van den Bergh RCN, Essink-Bot M-L, 2010

    Journal: Eur J Cancer
    Reference: 46(2010):3073-3081.

    paper

  • 425. Detection rates of cancer, high grade PIN and atypical lesions suspicious for cancer in the European Randomized Study of Screening for Prostate Cancer

    Laurila M, van der Kwast T, Bubendorf L, di Lollo S, Pihl CG, Ciatto S, Hugosson J, Määttänen L, Roobol MJ, Kujala PM, 2010

    Journal: Eur J Cancer
    Reference: 46(2010):3068-3072.

    paper

  • 424. Blinded and uniform causes of death verification in cancer screening: A major influence on the outcome of a prostate cancer screening trial?

    Otto SJ, van Leeuwen PJ, Hoekstra JW, Merckelbach JW, Blom JHM, Schröder FH, Roobol MJ, de Koning HJ, 2010

    Journal: Eur J Cancer
    Reference: 46(2010):3061-3067.

    paper

  • 423. PSA levels and cancer detection rate by centre in the European Randomized Study of Screening for Prostate Cancer

    Otto SJ, Moss SM, Määttänen L, Roobol MJ, Zappa M, Nelen V, Kwiatkowski M, Villers A, Hugosson J, Berenguer Sanchez A, de Koning HJ, 2010

    Journal: Eur J Cancer
    Reference: 46(2010):3053-3060.

    paper

  • 422. Prostate cancer incidence and mortality trends in 37 European countries: An overview

    Bray F, Lortet-Tieulent J, Ferlay J, Forman D, Auvinen A, 2010

    Journal: Eur J Cancer
    Reference: 46 (2010):3040-3052

    paper

← PreviousNext →